| Stereochemistry | ACHIRAL |
| Molecular Formula | C19H25N3OS |
| Molecular Weight | 343.486 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CCCCOC1=CC=C(NC(=S)NC2=CC=C(C=C2)N(C)C)C=C1
InChI
InChIKey=JYCBKPOKWDDOOV-UHFFFAOYSA-N
InChI=1S/C19H25N3OS/c1-4-5-14-23-18-12-8-16(9-13-18)21-19(24)20-15-6-10-17(11-7-15)22(2)3/h6-13H,4-5,14H2,1-3H3,(H2,20,21,24)
| Molecular Formula | C19H25N3OS |
| Molecular Weight | 343.486 |
| Charge | 0 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Thiambutosine is a carbanilide derivative patented by Imperial Chemical Industries Ltd. as the antituberculous agent. In vitro, the resistance of Mycobacterium tuberculosis H37Rv to Thiambutosine develops more slowly than resistance to streptomycin, p-aminosalicylic acid, or isoniazid. A sub-inhibiting concentration of Thiambutosine with either streptomycin or isoniazid considerably retards the emergence of strains resistant to these two agents.
Originator
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
